Plasma exchange in immune-mediated neuropathies

Current Opinion in Neurology

Volumn 21, Issue 5, 2008, Pages 547-554

  Lehmann, Helmar C ^a   Hartung, Hans Peter ^a   Zu Hörste, Gerd Meyer ^a   Kieseier, Bernd C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Antiganglioside antibodies; Guillain Barr syndrome; Multifocal motor neuropathy; Plasma exchange

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; GANGLIOSIDE ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

ASSISTED VENTILATION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOADSORPTION; IMMUNOPATHOLOGY; MONOCLONAL IMMUNOGLOBULINEMIA; MOTOR NEUROPATHY; MOTOR PERFORMANCE; NEUROPATHY; PLASMAPHERESIS; POLYRADICULONEUROPATHY; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PARAPROTEINEMIAS; PERIPHERAL NERVOUS SYSTEM DISEASES; PLASMA EXCHANGE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; TREATMENT OUTCOME;

EID: 53549099910     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32830b0f61     Document Type: Review

References (71)

1. Lehmann HC, Hartung H-P, Hetzel GR, et al. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neural 2006; 63:1066-1071.
2. Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2006; 11:30-46.
3. Korach JM, Berger P, Gìraud C, et al. Role of replacement fluids in the immediate complications of plasma exchange. French Registry Cooperative Group. Intensive Care Med 1998; 24:452-458.
4. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22:753-761.
5. Kankirawatana S, Huang ST, Marques MB. Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange. J Clin Apher 2007; 22:265-269.
6. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366:1653-1666.
7. Kieseier BC, Kiefer R, Gold R, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004; 30:131-156.
8. Hartung HP, Kieseier BC, Kiefer R. Progress in Guillain-Barré syndrome. Curr Opin Neurol 2001; 14:597-604.
9. Halstead SK, Humphreys PD, Goodfellow JA, et al. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann Neurol 2005; 58:203-210.
10. Overell JR, Willison HJ. Recent developments in Miller Fisher syndrome and related disorders. Curr Opin Neurol 2005; 18:562-566.
11. Willison HJ. The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst 2005; 10:94-112.
12. Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996; 39:17-28.
13. Sheikh KA, Ho TW, Nachamkin I, et al. Molecular mimicry in Guillain-Barré syndrome. Ann N Y Acad Sci 1998; 845:307-321.
14. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci U S A 2004; 101:11404-11409.
15. Yuki N, Odaka M. Ganglioside mimicry as a cause of Guillain-Barré syndrome. Curr Opin Neurol 2005; 18:557-561.
16. Goodfellow JA, Bowes T, Sheikh K, et al. Overexpression of GD1 a ganglioside sensitizes motor nerve terminals to anti-GD1 a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci 2005; 25:1620-1628.
17. Zhang G, Lopez PH, Li CY, et al. Antiganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004; 127:1085-1100.
18. Buchwald B, Zhang G, Vogt-Eisele AK, et al. Antiganglioside antibodies alter presynaptic release and calcium influx. Neurobiol Dis 2007; 28:113-121.
19. Susuki K, Rasband MN, Tohyama K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007; 27:3956-3967. An elegant experimental study in which the authors demonstrate pathogenic effects of anti-GM1 antibodies at the level of the nodes of Ranvier. It provides a further rationale for the use of plasma exchange in GBS.
20. Lehmann HC, Lopez PH, Zhang G, et al. Passive immunization with antiganglioside antibodies directly inhibits axon regeneration in an animal model. J Neurosci 2007; 27:27-34.
21. Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996; 39:625-635.
22. Meyer zu Horste G, Hartung HP, Kieseier BC. From bench to bedside: experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 2007; 3:198-211.
23. Greenwood RJ, Newsom-Davis J, Hughes RA, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 1:877-879.
24. Osterman PO, Fagius J, Lundemo G, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 2:1296-1299.
25. Farkkila M, Kinnunen E, Haapanen E, Livanainen M. Guillain-Barré syndrome: quantitative measurement of plasma exchange therapy. Neurology 1987; 37:837-840.
26. The Guillain-Barré syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35:1096-1104.
27. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997; 41:298-306.
28. Yuki N, Tagawa Y, Hirata K. Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barré syndrome. Neurology 1998; 51:875-877.
29. Sanjay R, Flanagan J, Sodano D, et al. The acute phase reactant, fibrinogen, as a guide to plasma exchange therapy for acute Guillain- Barré syndrome. J Clin Apher 2006; 21:105-110. According to this study, a high degree of fibrinogen decrease during plasma exchange is associated with better neurological outcome in GBS. Since fibrinogen is routinely measured during plasma exchange, it may represent a very feasible, useful marker for treatment efficacy.
30. Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2006: CD002063.
31. Hughes RA, Swan AV, Raphael JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007; 130:2245-2257. A comprehensive meta-analysis of the available treatment options in GBS.
32. Kaynar L, Altuntas F, Aydogdu I, et al. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study. Transfus Apher Sci 2008; 38:109-115.
33. Yucesan C, Arslan O, Arat M, et al. Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases. Transfus Apher Sci 2007; 36:103-107.
34. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. The Dutch Guillain-Barré Study Group. N Engl J Med 1992; 326:1123-1129.
35. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349:225-230.
36. Haupt WF, Rosenow F, van der Ven C, Birkmann C. Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis. Ther Apher 2000; 4:195-197.
37. Okamiya S, Ogino M, Ogino Y, et al. Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barré syndrome. Ther Apher Dial 2004; 8:248-253.
38. Arakawa H, Yuhara Y, Todokoro M, et al. Immunoadsorption therapy for a child with Guillain-Barré syndrome subsequent to Mycoplasma infection: a case study. Brain Dev 2005; 27:431-433.
39. Willison HJ, Townson K, Veitch J, et al. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1 b antibodies from autoimmune neuropathy sera. Brain 2004; 127:680-691.
40. Andersen SM, Ling CC, Zhang P, et al. Synthesis of ganglioside epitopes for oligosaccharide specific immunoadsorption therapy of Guillian-Barré syndrome. Org Biomol Chem 2004; 2:1199-1212.
41. Esperou H, Jars-Guincestre MC, Bolgert F, et al. Cost analysis of plasmaexchange therapy for the treatment of Guillain-Barré syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Intensive Care Med 2000; 26:1094-1100.
42. Nagpal S, Benstead T, Shumak K, et al. Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis. J Clin Apher 1999; 14:107-113.
43. Tsai CP, Wang KC, Liu CY, et al. Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin. J Clin Neurosci 2007; 14:625-629.
44. Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating neuropathy. N Engl J Med 2005; 352:1343-1356.
45. Yuki N, Tagawa Y, Handa S. Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG, and SGPG in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1996; 70:1-6.
46. Kwa MS, van Schaik IN, De Jonge RR, et al. Autoimmunoreactivity to Schwann cells in patients with inflammatory neuropathies. Brain 2003; 126:361-375.
47. Koski CL Therapy of CIDP and related immune-mediated neuropathies. Neurology 2002; 59:S22-27.
48. Toyka KV, Gold R. The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents. Neurology 2003; 60:S2-S7.
49. Sutton U, Winer JB. Immunosuppression in peripheral neuropathy: rationale and reality. Curr Opin Pharmacol 2002; 2:291-295.
50. Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986; 314:461-465.
51. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119:1055-1066.
52. Mehndiratta MM, Singh AC. Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy. Curr Allergy Asthma Rep 2007; 7:274-279.
53. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004:CD003906. A meta-analysis of plasma exchange in CIDP. It excellently summarizes the data of randomized controlled trials documenting a short-term benefit of plasma exchange in CIDP.
54. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neural 1994; 36:838-845.
55. Hughes RA, Bouche P, Cornblath DR, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neural 2006; 13:326-332.
56. Chan YC, Allen DC, Fialho D, et al. Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J Neural Neurosurg Psychiatry 2006; 77:114-116.
57. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of muttifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2006; 11:1-8.
58. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, et al. Muttifocal motor neuropathy. Lancet Neural 2005; 4:309-319.
59. Nobile-Orazk) E. Muttifocal motor neuropathy. J Neuroimmunol 2001; 115:4-18.
60. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004; 291:2367-2375.
61. Leger JM, Chassandre B, Musset L, et al. Intravenous immunoglobulin therapy in murtifocal motor neuropathy: a double-blind, placebo-controHed study. Brain 2001; 124:145-153.
62. Pestrank A, Cornblath DR, liyas A, et al. A treatable multifocal motor neuropathy with antbodies to GM1 ganglioside. Ann Neural 1988; 24:73-78.
63. Specht S, Claus D, Zieschang M. Plasmapheresis in muttifocal motor neuropathy: a case report. J Neural Neurosurg Psychiatry 2000; 68:533-535.
64. Lehmann HC, Hoffmann FR, Fusshoeller A, et al. The therapeutic value of plasma exchange in murtifocal motor neuropathy. J Neural Sci 2008; 14 May [Epub ahead of print].
65. Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neural 2001; 49:712-720.
66. Nobile-Orazio E. IgM paraproleinaemic neuropathies. Curr Opin Neural 2004; 17:599-605.
67. Vital A. Paraproteinemic neuropathies. Brain Pathol 2001; 11:399-407.
68. Allen D, Lunn MP, Niermeijer J, Nobile-Orazio E Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database Syst Rev 2007:CD005376.
69. Lunn MP, Nobile-Orazio E Immunotherapy for lgM antimyelin-associated gfycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2006:CD002827. An excellent meta-analysis of the immunotherapy in polyneuropathies associated with IgM parapratein.
70. Hadden RD, Nobile-Orazio E, Sommer C, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neural 2006; 13:809-818.
71. Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991; 325:1482-1486.